Key statistics
Short selling activityProvided by S&P Global Market Intelligence
| Open | -- |
|---|---|
| High | 591.36 |
| Low | 591.36 |
| Bid | -- |
| Offer | -- |
| Previous close | 736.13 |
| Average volume | -- |
|---|---|
| Shares outstanding | 77.28m |
| Free float | 76.83m |
| P/E (TTM) | -- |
| Market cap | 3.21bn USD |
| EPS (TTM) | -3.88 USD |
Data delayed at least 20 minutes, as of Feb 12 2026.
More ▼
Announcements
- Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Xenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare Conference
- Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference
- Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025
- Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Xenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025
- Xenon to Present New Azetukalner OLE Study Data in Epilepsy at AES 2025
- Xenon to Present at Upcoming Investor Conferences
- Xenon Reports Third Quarter 2025 Financial Results & Business Update
- Xenon to Report Q3 2025 Financial Results on November 3, 2025
More ▼
